Abdalla A. Saad

Mr. Saad has been instrumental in launching Co-D Therapeutics where he is involved in business development, fund raising, and technology licensing. He assisted in securing funding through WARF’s Accelerator Program to develop Triolimus. Prior to Co-D, Mr. Saad held positions as a research scientist at the University of Wisconsin-Madison where he developed expertise in drug screening techniques and technology evaluation. Mr. Saad has worked for both the Wisconsin Entrepreneurs’ Network and the Venture Capital Group at Burrill & Company. Mr. Saad received his B.S. in Zoology and M.S. in Biotechnology from the University of Wisconsin-Madison.